Blog
RSS FeedPosted by Michael Wonder on 08 Jul 2018
CADTH publishes initial pERC recommendation for Roche's alectinib hydrochloride
6 July 2018 - The outcome relates to the use of alectinib hydrochloride (Alecensaro) for the first-line treatment of patients ...
Posted by Michael Wonder on 11 Mar 2018
The relative importance of clinical, economic, patient values and feasibility criteria in cancer drug reimbursement in Canada: a revealed preferences analysis of recommendations of the pan-Canadian Oncology Drug Review 2011–2017
20 January 2018 - Most Canadian provinces and territories rely on the pan-Canadian Oncology Drug Review to provide recommendations regarding public ...
Posted by Michael Wonder on 25 Sep 2017
First-in-class BRCA-positive ovarian cancer medicine Lynparza (olaparib) receives positive pan-Canadian Oncology Drug Review recommendation for provincial reimbursement
21 September 2017 - This marks an important first step towards providing Canadian women with access to this treatment. ...
Posted by Michael Wonder on 05 Sep 2017
CADTH recommends olaparib following supply of results from phase 3 trial
5 September 2017 - CADTH has published its initial recommendation for olaparib for use as monotherapy maintenance treatment of adult patients ...
Posted by Michael Wonder on 05 Sep 2017
CADTH publishes final outcome for Opdivo for head and neck cancer
5 September 2017 - CADTH has completed its assessment of nivolumab for the treatment of adults with recurrent or metastatic ...
Posted by Michael Wonder on 03 Aug 2017
CADTH publishes initial recommendation for daratumumab
3 August 2017 - CADTH has published its initial recommendation on the use of daratumumab for use in combination with ...
Posted by Michael Wonder on 03 Aug 2017
CADTH publishes initial recommendation for Keytruda
3 August 2017 - CADTH has published its initial recommendation on the use of pembrolizumab for use by untreated patients ...
Posted by Michael Wonder on 05 Jun 2017
CADTH publishes final outcome for Gazyva for new indication
2 June 2017 - The Canadian pERC has recommended the funding of obinutuzumab (Gazyva) for use by adults with non-Hodgkin's ...
Posted by Michael Wonder on 09 May 2017
Pan-Canadian Oncology Drug Review recommendation supports the use of Tagrisso (osimertinib) as the standard of care for T790M mutated non-small-cell lung cancer
8 May 2017 - AstraZeneca is committed to rapid and collaborative discussions with pan-Canadian Pharmaceutical Alliance and provinces to get ...
Posted by Michael Wonder on 05 May 2017
Engaging specialist oncologists in the assessment of oncology drugs in Canada
1 May 2017 - The assessment of new cancer drugs in Canada increasingly engages specialist oncology physicians. This has not always ...
Posted by Michael Wonder on 31 Mar 2017
pERC publishes initial recommendation for Roche's Gazyva
30 March 2017 - The outcome relates to the use of obinutuzumab in combination with chemotherapy followed by obinutuzumab monotherapy ...
Posted by Michael Wonder on 30 Mar 2017
pERC publishes final recommendation for Sanofi Genzyme's Caprelsa
30 March 2017 - The recommendation relates to the use of vandetanib for the treatment of symptomatic and/or progressive medullary ...
Posted by Michael Wonder on 30 Mar 2017
pERC publishes final outcome for Amgen's Kyprolis
30 March 2017 - The outcome relates to the use of carfilzomib in combination with dexamethasone by patients with relapsed ...
Posted by Michael Wonder on 07 Mar 2017
What aspects of an economic evaluation are commercially sensitive?
6 March 2017 - Interesting insights from the pCODR Initial Economic Guidance Report for alectinib hydrochloide (Alecensaro). ...
Posted by Michael Wonder on 06 Mar 2017
CADTH publishes initial recommendations for three medicines for non-small-cell lung cancer
3 March 2016 - The outcome for three medicines, ceritinib (Zykadia), osimertinib mesylate (Tagrisso) and alectinib hydrochloride (Alecensaro), demonstrate the ...